Online Only Articles

Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan
Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto
Vol. 104 No. 8 (2019): August, 2019 https://doi.org/10.3324/haematol.2019.217141